Please login to the form below

Not currently logged in
Email:
Password:

EFPIA's Richard Torbett to move to the ABPI

Will take up commercial role at UK pharma bodyat the end of the month

ABPI Richard TorbettThe Association of the British Pharmaceutical Industry (ABPI) has appointed Richard Torbett as executive director - commercial UK.

He will take up the role at the end of this month, moving from European pharma trade association EFPIA, where he was chief economist and director of strategy.

Prior to this Torbett spent six years at Pfizer, where he was a senior director and head of international affairs.

In his new role Torbett will be responsible for heading up the ABPI's commercial strategy and leading its UK commercial team, and will report to the ABPI's chief executive.

Alison Clough, acting CEO, said: “With his wealth of knowledge and expertise, Richard will be very well placed to direct the ABPI's commercial strategy and to lead the UK commercial team.

“His experience in both government and the pharmaceutical industry will prove invaluable when addressing the issues of access and use of new medicines in the NHS and in leading discussions with the Department of Health around the PPRS.”

At the ABPI Torbett will focus on pricing, the Pharmaceutical Price Regulation Scheme (PPRS), health technology assessments (HTA) and value assessment, as well as market access in the UK.

22nd July 2015

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Attigo (part of the Mednet Group)

Inclusion drives innovation. Attigo, a social enterprise, helps pharma and the socially conscious business shape the future by engaging with...

Latest intelligence

US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...
Harness the power of data to map new patient pathways
Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset...
What NORD’s RareInsights® 30-year comparative analysis means to us and our clients at OPEN Health
...

Infographics